Liraglutide

Also known as: Victoza, Saxenda, GLP-1 analog

Evidence Tier Amedium riskintermediaterx approved

Once-daily GLP-1 receptor agonist with extensive clinical data for diabetes and obesity care.

Overview

Liraglutide is a daily GLP-1 receptor agonist used for type 2 diabetes and obesity. Human evidence is strong, though weight-loss efficacy is typically below semaglutide and tirzepatide. It remains clinically established, but as with other GLP-1 therapies, off-label research sourcing should not be treated as interchangeable with regulated pharmacy product.

Research Details

Mechanism of Action

GLP-1 receptor agonist that improves satiety and glucose-dependent insulin secretion while slowing gastric emptying.

Study Dose Range

Approved human use: 1.2 mg to 1.8 mg daily for diabetes; 3 mg daily for obesity.

Administration Routes

subcutaneous

Onset / Timeline

Metabolic and appetite effects begin within days to weeks; body-weight effects build over months.

Expected Effects

Moderate weight loss, improved satiety, and HbA1c reduction in clinical populations.

Adverse Effects

GI effects are common, especially nausea, vomiting, constipation, and diarrhea. Pancreatitis and gallbladder events remain class concerns.

Contraindications

Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history and pregnancy.

Interaction Notes

Same class cautions as other GLP-1 agents: hypoglycemia risk rises with insulin or sulfonylureas, and gastric emptying delay can affect oral medications.

Related Goals

Fat Loss & Metabolism

Known Interactions

contraindicated with Semaglutide

Two GLP-1 agonists in the same stack creates redundant mechanism and higher side-effect burden.

contraindicated with Tirzepatide

Dual incretin and GLP-1-only agonists should not be stacked in consumer protocols.

contraindicated with Retatrutide

Do not layer a daily GLP-1 agonist with an investigational triple-agonist compound.

Available From

No vendors currently listed for this peptide.

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Tesamorelin

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Tier A

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.